Chen Charles H, Zan Bing, Ulmschneider Jakob P, Wimley William C, Lu Timothy K, Ulmschneider Martin B, Zhou Liping
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Massachusetts, Boston, USA.
School of Physics and Astronomy, Institute of Natural Sciences, Shanghai Jiao Tong University, Shanghai, China.
J Pept Sci. 2023 Aug;29(8):e3482. doi: 10.1002/psc.3482. Epub 2023 Feb 11.
Membrane-active peptides play an essential role in many living organisms and their immune systems and counter many infectious diseases. Many have dual or multiple mechanisms and can synergize with other molecules, like peptides, proteins, and small molecules. Although membrane-active peptides have been intensively studied in the past decades and more than 3500 sequences have been identified, only a few received approvals from the US Food and Drug Administration. In this review, we investigated all the peptide therapeutics that have entered the market or were subjected to preclinical and clinical studies to understand how they succeeded. With technological advancement (e.g., chemical modifications and pharmaceutical formulations) and a better understanding of the mechanism of action and the potential targets, we found at least five membrane-active peptide drugs that have entered preclinical/clinical phases and show promising results for cancer treatment. We summarized our findings in this review and provided insights into membrane-active anticancer peptide therapeutics.
膜活性肽在许多生物体及其免疫系统中发挥着重要作用,并对抗多种传染病。许多膜活性肽具有双重或多种作用机制,并且可以与其他分子(如肽、蛋白质和小分子)协同作用。尽管在过去几十年中对膜活性肽进行了深入研究,已鉴定出3500多个序列,但只有少数获得了美国食品药品监督管理局的批准。在本综述中,我们研究了所有已进入市场或已进行临床前和临床研究的肽类疗法,以了解它们是如何取得成功的。随着技术进步(如化学修饰和药物制剂)以及对作用机制和潜在靶点的更好理解,我们发现至少有五种膜活性肽药物已进入临床前/临床阶段,并在癌症治疗中显示出有前景的结果。我们在本综述中总结了我们的发现,并提供了对膜活性抗癌肽疗法的见解。